王佳 張紅玉 孫曉靖
[摘要] 目的 研究重度顱腦損傷患者中性粒細(xì)胞明膠酶相關(guān)載脂蛋白(NGAL)及泛素C末端水解酶L1(uCH-L1)的表達(dá)變化及其在預(yù)后預(yù)測(cè)中的應(yīng)用。 方法 選取2015年6月~2017年1月新疆醫(yī)科大學(xué)第二附屬醫(yī)院56例重度顱腦損傷患者為研究對(duì)象,根據(jù)24 h內(nèi)的NGAL、uCH-L1水平將患者分別分為NGAL升高組(NGAL>4.40 ng/mL,38例)、非NGAL升高組(NGAL≤4.40 ng/mL,18例)和uCH-L1升高組(uCH-L1>0.38 ng/L,35例)、非uCH-L1升高組(uCH-L1≤0.38 ng/L,21例)。根據(jù)是否存活分為死亡組和生存組,比較各組相關(guān)指標(biāo)的差異,檢測(cè)各組NGAL和uCH-L1與預(yù)后的關(guān)系。 結(jié)果 與非NGAL升高組、非uCH-L1升高組比較,NGAL升高組、uCH-L1升高組患者入院時(shí)間較長(zhǎng),收縮壓(SBP)及舒張壓(DBP)較低,入院格拉斯哥昏迷量表(GCS)評(píng)分較低,急性生理學(xué)及慢性健康狀況評(píng)分系統(tǒng)(APACHEⅡ)評(píng)分較高,死亡率較高,差異均有統(tǒng)計(jì)學(xué)意義(P < 0.05或P < 0.01)。與生存組比較,死亡組NGAL、uCH-L1明顯升高,差異有高度統(tǒng)計(jì)學(xué)意義(P < 0.01)。NGAL與APACHEⅡ評(píng)分呈正相關(guān)(r = 0.799,P < 0.05),uCH-L1與APACHEⅡ評(píng)分及NGAL呈正相關(guān)(r = 0.659,P < 0.05;r = 0.726,P < 0.05)。 結(jié)論 重度顱腦損傷患者NGAL、uCH-L1變化方向與患者預(yù)后密切相關(guān),兩者明顯升高提示預(yù)后不良。
[關(guān)鍵詞] 重度顱腦損傷;中性粒細(xì)胞明膠酶相關(guān)載脂蛋白;泛素C末端水解酶L1
[中圖分類號(hào)] R651.15 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1673-7210(2018)10(b)-0116-04
[Abstract] Objective To explore the expression of neutrophil gelatinase associated lipocalin (NGAL) and ubiquitin C-terminal hydrolase-L1 (uCH-L1) in patients with severe craniocerebral injury and its application in prognosis prediction. Methods Fifty-six patients with severe craniocerebral injury in the Second Affiliated Hospital of Xinjiang Medical University from June 2015 to January 2017 were enrolled as study objects. According to the levels of NGAL and uCH-L1 within 24 hours, the patients were respectively divided into high NGAL group (NGAL>4.40 ng/mL, 38 cases), low NGAL group (NGAL≤4.40 ng/mL, 18 cases) and high uCH-L1 group (uCH-L1>0.38 ng/L, 35 cases), low uCH-L1 group (uCH-L1≤0.38 ng/L, 21 cases). According to whether they were survived, 56 patients were divided into death group and survival group. The differences of related indicators in each group were compared, and the relationship of the expression levels of NGAL and uCH-L1 in each group and its prognosis was detected. Results Compared with the low NGAL group and the low uCH-L1 group, the patients in high NGAL group and high uCH-L1 group had longer admission time, lower systolic blood pressure (SBP) and diastolic blood pressure (DBP), lower Glasgow coma scale (GCS) score on admission, higher acute physiology and chronic health evaluation (APACHEⅡ) score and higher mortality rate, the differences were statistically significant (P < 0.05 or P < 0.01). Compared with survival group, the NGAL and uCH-L1 in death group increased significantly, the differences were highly statistically significant (P < 0.01). The expression of NGAL was positively correlated with APACHEⅡ (r = 0.799,P < 0.05), and uCH-L1 was positively correlated with APACHEⅡ score and NGAL (r = 0.659, P < 0.05; r = 0.726,P < 0.05). Conclusion The changes of NGAL and uCH-L1 in patients with severe craniocerebral injury were closely related to the prognosis of patients, and the increase of NGAL and uCH-L1 indicates poor prognosis.
[Key words] Severe craniocerebral injury; Neutrophil gelatinase associated lipocalin; Ubiquitin C-terminal hydrolase-L1
顱腦損傷是臨床上較常見(jiàn)的創(chuàng)傷性疾病,臨床上將顱腦損傷后格拉斯哥昏迷量表(Glasgow coma scale,GCS)評(píng)分<8分的患者歸為重度顱腦損傷,重度顱腦損傷病死率高,給人們的經(jīng)濟(jì)及生活造成嚴(yán)重影響,早診斷早治療對(duì)于疾病的預(yù)后至關(guān)重要[1]。泛素C末端水解酶L1(ubiquitin C-terminal hydrolase-L1,uCH-L1)是一種去泛素化酶,主要存在于海馬神經(jīng)元胞體和樹突,對(duì)于海馬神經(jīng)元功能保持至關(guān)重要[2]。研究發(fā)現(xiàn),uCH-L1可作為反映顱腦損傷引起的血腦屏障損傷度的重要指標(biāo)之一[3],但關(guān)于顱腦損傷患者預(yù)后與uCH-L1水平相關(guān)性的研究較少。中性粒細(xì)胞明膠酶相關(guān)載脂蛋白(neutrophil gelatinase associated lipocalin,NGAL)是最近發(fā)現(xiàn)的一種蛋白,用于監(jiān)測(cè)全身性炎性反應(yīng),但其在重度顱腦損傷患者中的研究報(bào)道較少[4]。本研究旨在探討重度顱腦損傷患者血清uCH-L1及NGAL表達(dá)情況及其對(duì)患者預(yù)后預(yù)測(cè)價(jià)值。
1 資料與方法
1.1 一般資料
選取2015年6月~2017年1月新疆醫(yī)科大學(xué)第二附屬醫(yī)院住院治療的56例重度顱腦損傷患者為研究對(duì)象。納入標(biāo)準(zhǔn):年齡>14歲;外傷至住院時(shí)間<24 h;GCS評(píng)分>8分;住院時(shí)間>12 d。排除標(biāo)準(zhǔn):合并心肝脾腎血管系統(tǒng)疾??;合并其他臟器損傷;死亡可能性較大者;合并顱內(nèi)血管畸形;合并出血性疾病。顱腦損傷原因:交通事故31例,高處墜落或暴力25例。損傷類型:?jiǎn)渭兡X挫裂傷9例,硬膜下血腫9例,硬膜外血腫12例,蛛網(wǎng)膜下腔出血8例,顱內(nèi)多發(fā)損傷13例,其他5例。參照參考文獻(xiàn)[3-4]中NGAL的正常范圍為2.63~4.40 ng/mL,uCH-L1的正常水平為<0.38 ng/L,根據(jù)24 h內(nèi)的NGAL水平將患者分為NGAL升高組(NGAL>4.40 ng/mL,38例)、非NGAL升高組(NGAL ≤4.40 ng/mL,18例)和uCH-L1升高組(uCH-L1 >0.38 ng/L,35例)、非uCH-L1升高組(uCH-L1 ≤0.38 ng/L,21例)。根據(jù)住院30 d時(shí)生存狀態(tài)分為死亡組(24例)和生存組(32例)。所有入選對(duì)象或家屬簽訂知情同意書,本研究經(jīng)醫(yī)院醫(yī)學(xué)倫理委員會(huì)批準(zhǔn)。
1.2 觀察指標(biāo)
患者入院后記錄一般臨床資料、患者發(fā)病到入院時(shí)間、入院時(shí)急性生理學(xué)及慢性健康狀況評(píng)分系統(tǒng)(APACHEⅡ)評(píng)分及GCS評(píng)分。入院后立即抽取靜脈血5 mL,采用固相夾心酶聯(lián)免疫吸附法檢測(cè)患者血清NGAL及uCH-L1含量,嚴(yán)格按照試劑盒說(shuō)明書進(jìn)行操作。采用全自動(dòng)血細(xì)胞計(jì)數(shù)儀檢測(cè)白細(xì)胞數(shù)量。
1.3 統(tǒng)計(jì)學(xué)方法
本研究應(yīng)用GraphPad Prism 4.0軟件對(duì)數(shù)據(jù)進(jìn)行分析,計(jì)量資料以均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,數(shù)據(jù)在滿足正態(tài)分布情況下,采用t檢驗(yàn),計(jì)數(shù)資料以百分率表示,采用χ2檢驗(yàn),NGAL、uCH-L1水平相關(guān)性采用Pearson相關(guān)分析。以P < 0.05為差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1 不同NGAL、uCH-L1水平分組之間的一般臨床資料及相關(guān)指標(biāo)比較
與非NGAL升高組、非uCH-L1升高組比較,NGAL升高組、uCH-L1升高組患者入院時(shí)間較長(zhǎng),收縮壓(SBP)及舒張壓(DBP)較低,入院GCS評(píng)分較低,APACHEⅡ評(píng)分較高,死亡率較高,差異均有統(tǒng)計(jì)學(xué)意義(P < 0.05或P < 0.01)。見(jiàn)表1~2。
2.2 生存組和死亡組NGAL、uCH-L1水平比較
與生存組比較,死亡組NGAL、uCH-L1水平更高,差異有高度統(tǒng)計(jì)學(xué)意義(P < 0.01)。見(jiàn)表3。
2.3 重度顱腦損傷患者NGAL、uCH-L1與APACHEⅡ評(píng)分相關(guān)性分析
NGAL與APACHEⅡ評(píng)分呈正相關(guān)(r = 0.799,P = 0.028);uCH-L1與APACHEⅡ評(píng)分呈正相關(guān)(r = 0.659,P = 0.041)。NGAL與uCH-L1呈正相關(guān)(r = 0.726,P = 0.032)。見(jiàn)圖1~3。
3 討論
顱腦損傷是神經(jīng)外科的常見(jiàn)疾病之一,死亡率高,致殘率高,因此對(duì)病情的變化做出準(zhǔn)確判斷至關(guān)重要。臨床癥狀、GCS評(píng)分、影像學(xué)檢查都是常用的方法[5]。但目前各種方法均難以定量,因此尋找簡(jiǎn)便易行的觀察指標(biāo)是研究顱腦損傷的一個(gè)重要課題。近年來(lái)一些學(xué)者將血液生化指標(biāo)應(yīng)用于顱腦損傷的臨床研究。本研究觀察了uCH-L1及NGAL在重度顱腦損傷患者中的表達(dá)情況及預(yù)測(cè)預(yù)后的價(jià)值。
uCH-L1屬低分子量的去泛素化酶,在海馬神經(jīng)元胞體和樹突中均有分布,以維持海馬神經(jīng)元的正常突觸結(jié)構(gòu)和功能[6]。有研究表明,重度顱腦損傷患者血清uCH-L1水平明顯高于正常人群,與GCS評(píng)分和顱腦CT表現(xiàn)密切相關(guān),彌漫性損傷患者的血清uCH-L1水平顯著高于輕微損傷者,uCH-L1是顱腦損傷患者死亡率的獨(dú)立危險(xiǎn)因素[7]。另外有研究表明,重型顱腦損傷患者腦脊液中uCH-L1含量高于對(duì)照組,與GCS評(píng)分、CT表現(xiàn)及傷后6周死亡率密切相關(guān)[8]。有研究提示GCS評(píng)分3~5分的患者傷后12 h和24 h的uCH-L1水平明顯高于GCS評(píng)分6~8分者;死亡及預(yù)后不良的患者uCH-L1水平均明顯升高[9]。有學(xué)者觀察到95例重度創(chuàng)傷性腦損傷患者(GCS評(píng)分≤8分)急性期血清和腦脊液uCH-L1水平顯著升高,且與損傷嚴(yán)重程度及生存預(yù)后密切相關(guān)[10]。故認(rèn)為uCH-L1是判斷腦損傷嚴(yán)重程度的一種新型生物標(biāo)志物。目前,國(guó)內(nèi)關(guān)于uCH-L1與顱腦損傷的相關(guān)性研究較少,尚處于初始階段,多數(shù)為小樣本研究,此外uCH-L1與腦損傷機(jī)制及病理生理過(guò)程的關(guān)系尚不明確[11-12]。本研究結(jié)果顯示,與非uCH-L1升高組比較,uCH-L1升高組患者入院時(shí)間較長(zhǎng),SBP及DBP較低,入院GCS評(píng)分較低,APACHEⅡ評(píng)分較高,死亡率較高,同時(shí)死亡組患者uCH-L1水平較存活組高。這些都提示uCH-L1水平可以作為重度顱腦損傷患者的預(yù)后評(píng)價(jià)指標(biāo)。
NGAL是1993年Kjeldsen首次發(fā)現(xiàn)的糖蛋白[13]。研究表明NGAL可以通過(guò)二硫鍵與基質(zhì)金屬蛋白酶(MMP)-9結(jié)合,調(diào)節(jié)MMP-9活性[14-18]。我們知道MMP-9在顱內(nèi)出血后繼.發(fā)腦損傷中發(fā)揮至關(guān)重要的重要,那么NGAL在腦損傷中是否也起到一定的作用?戴芳等[19]研究表明,腦出血后血腫周圍組織NGAL蛋白及mRNA表達(dá)均升高,且腦出血模型組NGAL蛋白表達(dá)水平與神經(jīng)功能缺損程度呈正相關(guān)。楊美平[20]研究提示重度顱腦損傷合并急性腎損傷患者NGAL水平顯著高于正常組,且Ⅲ期組明顯高于Ⅰ期組及Ⅱ期組,死亡患者NGAL明顯高于存活患者。楊永麗等[21]研究發(fā)現(xiàn),重度顱腦損傷后2 h血清NGAL即可明顯升高,血清NGAL可作為重度顱腦損傷后診斷急性腎損傷的早期標(biāo)志物。本研究結(jié)果顯示,與非NGAL升高組比較,NGAL升高組患者入院時(shí)間較長(zhǎng),SBP及DBP較低,入院GCS評(píng)分較低,APACHEⅡ評(píng)分較高,死亡率較高,同時(shí)死亡組患者血清NGAL水平顯著高于存活組,這提示血清NGAL可評(píng)估重度顱腦損傷患者的預(yù)后。同時(shí)研究結(jié)果顯示血清NGAL水平與APACHEⅡ評(píng)分呈正相關(guān),提示血清NGAL水平可以反映顱腦損傷的嚴(yán)重程度。
綜上所述,uCH-L1及NGAL水平與重度顱腦損傷患者近期預(yù)后密切相關(guān),可能是患者近期死亡的獨(dú)立危險(xiǎn)因素,早期檢測(cè)對(duì)于評(píng)估患者病情及近期預(yù)后具有一定意義。
[參考文獻(xiàn)]
[1] Alali AS,F(xiàn)owler RA,Mainprize TG,et al. Intracranial Pressure Monitoring in Severe Traumatic Brain Injury:Results from the American College of Surgeons Trauma Quality Improvement Program [J]. J Neurotrauma,2013,30(20):1737-1746.
[2] 李莉,古正濤,劉志鋒,等.泛素羧基末端水解酶-1在重癥中暑小鼠腦損傷組織中的表達(dá)[J].醫(yī)學(xué)研究生學(xué)報(bào),2015,28(2):118-122.
[3] 丁濤.重型顱腦損傷急性期顱內(nèi)壓變化與泛素C末端水解酶L1、神經(jīng)元特異性烯醇化酶血清濃度的關(guān)系[J].現(xiàn)代實(shí)用醫(yī)學(xué),2015,27(11):1435-1436.
[4] Wenners AS,Mehta K,Loibl S,et al. Neutrophil gelatinase associated lipocalin(NGAL)predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer [J]. PLoS One,2012,7(10):e45826.
[5] Forde CT,Karri SK,Young AM,et al. Predictive markers in traumatic brain injury: opportunities for a serum biosignature [J]. Br J Neurosurg,2014,28(1):8-15.
[6] 李寧,任長(zhǎng)虹,吉訓(xùn)明.腦外傷生物標(biāo)記物的研究進(jìn)展[J].中國(guó)醫(yī)藥,2012,7(9):1188-1190.
[7] 葛嶺,薛龍,黃曉偉,等.輕型顱腦損傷患者血清UCH-L1變化的臨床意義和患者預(yù)后關(guān)系[J].醫(yī)學(xué)研究雜志,2014,43(7):116-118.
[8] 裘申忠,李珺,呂慶平,等.重型腦外傷患者血漿泛素羧基末端水解酶-1水平的變化及預(yù)后因素分析[J].浙江醫(yī)學(xué),2012,34(12):971-973.
[9] Mondello S,Linnet A,Buki A,et al. Clinical Utility of Serum Levels of Ubiquitin C-Terminal Hydrolase as a Biomarker for Severe Traumatic Brain Injury [J]. Neurosurgery,2012, 70(3):666-675.
[10] Brophy GM,Mondello S,Papa L,et al. Biekinetic analysis of ubiquitin C-terminal hydmlase-L1(UCH-L1)in servere traumatic brain injury patient biofluids [J]. J Neurotrauma,2011,28(6):861-870.
[11] Diaz-Arrastia R,Wang KK,Papa L,et al. Acute biomarkers of traumatic brain injury:relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein [J]. J Neurotrauma,2014,31(1):19-25.
[12] Li J,Yu C,Sun Y,et al. Serum ubiquitin C-terminal hydrolase L1 as a biomarker for traumatic brain injury:a systematic review and meta-analysis [J]. Am J Emerg Med,2015,33(9):1191-1196.
[13] Mondello S,Linnet A,Buki A,et al. Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury [J]. Neurosurgery,2012,70(3):666-675.
[14] 丁漣沭.創(chuàng)傷性腦損傷后標(biāo)志物的研究進(jìn)展[J].中華神經(jīng)創(chuàng)傷外科電子雜志,2015,1(1):42-44.
[15] Li N,Zhao WG,Xu FL,et al. Neutrophil gelatinase-associated lipocalin as an early marker of acute kidney injury in patients with traumatic brain injury [J]. J Nephrol,2013,26(6):1083-1088.
[16] Ronco C,Legrand M,Goldstein SL,et al. Neutrophil gelatinase-associated lipocalin: ready for routine clinical use? An international perspective [J]. Blood Purif,2014,37(4):271-285.
[17] Zhao J,Chen H,Zhang M,et al. Early expression of serum neutrophil gelatinase-associated lipocalin(NGAL)is associated with neurological severity immediately after traumatic brain injury [J]. J Neurol Sci,2016,368:392-398.
[18] 徐興凱,李巖,余猛進(jìn),等.尿中性粒細(xì)胞明膠酶相關(guān)脂質(zhì)運(yùn)載蛋白在危重病患者急性腎損傷早期診斷中的意義[J].中華急診醫(yī)學(xué)雜志,2013,22(5):505-510.
[19] 戴芳,王姍姍,許宏偉.中性粒細(xì)胞明膠酶相關(guān)載脂蛋白在大鼠腦出血后繼發(fā)性腦損傷中的作用研究[J].國(guó)際神經(jīng)病學(xué)神經(jīng)外科學(xué)雜志,2016,43(4):292-296.
[20] 楊美平.重型顱腦損傷并發(fā)急性腎損傷患者NGAL和Cys C水平變化及診斷價(jià)值[J].中國(guó)實(shí)用神經(jīng)疾病雜志,2016,19(19):110-112.
[21] 楊永麗,楊曉,何靜,等.NGAL和Cys C對(duì)重型顱腦損傷并發(fā)急性腎損傷的早期診斷價(jià)值[J].臨床腎臟病雜志,2014,14(8):461-465.
(收稿日期:2018-05-23 本文編輯:張瑜杰)